Literature DB >> 15490976

Radiosensitization of colon cancer cell lines by docetaxel: mechanisms of action.

Amanda L Dunne1, Carmel Mothersill, Tracy Robson, George D Wilson, David G Hirst.   

Abstract

The radiation-modifying action of docetaxel in experimental systems is well established. Docetaxel is also an increasingly important drug for the treatment of cancer in concurrent radiotherapy protocols. However, the mechanisms of docetaxel radiosensitization are not fully understood. We have investigated the magnitude and mechanisms of docetaxel radiosensitization in vitro in four human colorectal cancer cell lines (SW480, SW707, SW48, and HT29) with widely differing radiosensitivities. Cell survival curves were generated for a range of docetaxel concentrations (5-20 nM) alone and for X-rays (1-5 Gy) +/- 10 or 20 nM docetaxel (for 24 h before irradiation). Cell cycle distributions and apoptotic frequencies were measured during the treatments. Sensitivity to docetaxel alone was similar in all cell lines and could be attributed to massive induction of apoptosis (60-80% by 24 h). Radiosensitivity varied widely; the surviving fractions at 2 Gy in the most resistant (HT29) and most sensitive (SW28) lines were 0.81 and 0.13, respectively. Exposure to 10 nM docetaxel induced a progressive accumulation of SW480, SW707, and SW48 cells in G2/M. After 24 h, 55-70% of the cells were in G2/M. It is likely, therefore, that accumulation in this radiosensitive phase of the cell cycle contributes significantly to radiosensitization by the drug.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15490976     DOI: 10.3727/0965040041791455

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  10 in total

1.  Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies.

Authors:  Suneil Jain; Jonathan A Coulter; Alan R Hounsell; Karl T Butterworth; Stephen J McMahon; Wendy B Hyland; Mark F Muir; Glenn R Dickson; Kevin M Prise; Fred J Currell; Joe M O'Sullivan; David G Hirst
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-20       Impact factor: 7.038

2.  Docetaxel-based preoperative chemoradiation in localized gastric cancer: impact of pathological complete response on patient outcome.

Authors:  Y Rostom; H Zaghloul; G Khedr; W El-Shazly; D Abd-Allah
Journal:  J Gastrointest Cancer       Date:  2013-06

3.  Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.

Authors:  Marcus P Kelly; Sze Ting Lee; F-T Lee; Fiona E Smyth; Ian D Davis; Martin W Brechbiel; Andrew M Scott
Journal:  Prostate       Date:  2009-01-01       Impact factor: 4.104

4.  KPU-300, a Novel Benzophenone-Diketopiperazine-Type Anti-Microtubule Agent with a 2-Pyridyl Structure, Is a Potent Radiosensitizer That Synchronizes the Cell Cycle in Early M Phase.

Authors:  Kohei Okuyama; Atsushi Kaida; Yoshiki Hayashi; Yoshio Hayashi; Kiyoshi Harada; Masahiko Miura
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

5.  Chemoradiation therapy with docetaxel in elderly patients with stage II/III esophageal cancer: A phase 2 trial.

Authors:  Akihiro Ohba; Ken Kato; Yoshinori Ito; Chikatoshi Katada; Hiromichi Ishiyama; Sachiko Yamamoto; Takashi Ura; Takeshi Kodaira; Shigehiro Kudo; Yoshio Tamaki
Journal:  Adv Radiat Oncol       Date:  2016-07-15

6.  Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.

Authors:  Jun-Fang Liao; Qun Zhang; Xiao-Jing Du; Mei Lan; Shan Liu; Yun-Fei Xia; Xiu-Yu Cai; Wei Luo
Journal:  Cancer Commun (Lond)       Date:  2019-06-27

Review 7.  Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer.

Authors:  Tyrillshall S T Damiana; Simone U Dalm
Journal:  Pharmaceutics       Date:  2021-05-07       Impact factor: 6.321

8.  The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer-a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report.

Authors:  Masha Maharaj; Lucille Heslop; Trisha Govender; Nisaar Korowlay; Aviral Singh; Partha Choudhary; Mike Sathekge
Journal:  Nucl Med Mol Imaging       Date:  2021-04-13

9.  Butyrate enhances the efficacy of radiotherapy via FOXO3A in colorectal cancer patient‑derived organoids.

Authors:  Misun Park; Junhye Kwon; Hye-Jin Shin; Sun Mi Moon; Sang Bum Kim; Ui Sup Shin; Young-Hoon Han; Younjoo Kim
Journal:  Int J Oncol       Date:  2020-10-13       Impact factor: 5.650

10.  Thymoquinone Radiosensitizes Human Colorectal Cancer Cells in 2D and 3D Culture Models.

Authors:  Samar Al Bitar; Farah Ballout; Alissar Monzer; Mariam Kanso; Nour Saheb; Deborah Mukherji; Walid Faraj; Ayman Tawil; Samer Doughan; Maher Hussein; Wassim Abou-Kheir; Hala Gali-Muhtasib
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.